Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2023-03-15 Sale | 2023-03-17 9:02 pm | Prometheus Biosciences Inc. | RXDX | McKenna Mark C. Chairman, President & CEO | 25,000 | $116.14 | $2,903,500 | 338,777 (Direct) | View |
| 2023-03-01 Sale | 2023-03-03 9:30 pm | Prometheus Biosciences Inc. | RXDX | McKenna Mark C. Chairman, President & CEO | 11,320 | $125.14 | $1,416,563 | 1,029,214 (Direct) | View |
| 2023-02-15 Sale | 2023-02-17 9:31 pm | Prometheus Biosciences Inc. | RXDX | McKenna Mark C. Chairman, President & CEO | 63,680 | $120.82 | $7,693,618 | 1,363,547 (Direct) | View |
| 2023-01-17 Sale | 2023-01-19 8:39 pm | Prometheus Biosciences Inc. | RXDX | McKenna Mark C. Chairman, President & CEO | 25,000 | $118.99 | $2,974,750 | 388,777 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-07-17 Option Award | 2024-07-19 4:31 pm | N/A 2034-07-17 | NewAmsterdam Pharma Co N.V. | NAMS | McKenna Mark C. Director | 72,500 | $0 | 72,500 (Direct) | View |
Ownership | 2024-06-11 6:00 pm | N/A N/A | Perceptive Capital Solutions Corp | PCSC | McKenna Mark C. Director | 0 | $0 | 30,000 (Direct) | View |
| 2024-06-05 Option Award | 2024-06-07 8:05 pm | N/A 2034-06-05 | Apogee Therapeutics Inc. | APGE | McKenna Mark C. Director | 10,370 | $0 | 10,370 (Direct) | View |
Ownership | 2024-02-08 9:59 pm | N/A N/A | Helix Acquisition Corp. II | HLXB | McKenna Mark C. Director | 0 | $0 | 30,000 (Direct) | View |
| 2024-02-01 Option Award | 2024-02-05 5:29 pm | N/A 2034-02-01 | Spyre Therapeutics Inc. | SYRE | McKenna Mark C. Director | 40,000 | $0 | 40,000 (Direct) | View |
Ownership | 2024-02-05 5:25 pm | N/A 2033-11-22 | Spyre Therapeutics Inc. | SYRE | McKenna Mark C. Director | 0 | $0 | 477,000 (Direct) | View |
| 2023-08-17 Option Award | 2023-08-21 4:06 pm | N/A 2033-08-17 | Apogee Therapeutics Inc. | APGE | McKenna Mark C. Director | 150,000 | $0 | 200,000 (Direct) | View |
| 2023-06-16 Disposition | 2023-06-16 4:00 pm | N/A 2029-11-06 | Prometheus Biosciences Inc. | RXDX | McKenna Mark C. Chairman, President and CEO | 2,205,545 | $0 | 0 (Direct) | View |
| 2023-06-02 Exercise | 2023-06-02 7:13 pm | N/A N/A | Prometheus Biosciences Inc. | RXDX | McKenna Mark C. Chairman, President & CEO | 122,528 | $2.9 | 471,882 (Direct) | View |
| 2023-06-02 Exercise | 2023-06-02 7:13 pm | N/A N/A | Prometheus Biosciences Inc. | RXDX | McKenna Mark C. Chairman, President & CEO | 3 | $1.7 | 471,882 (Direct) | View |
| 2023-06-02 Exercise | 2023-06-02 7:13 pm | N/A 2029-11-06 | Prometheus Biosciences Inc. | RXDX | McKenna Mark C. Chairman, President & CEO | 122,531 | $0 | 471,882 (Direct) | View |
| 2023-03-15 Exercise | 2023-03-17 9:02 pm | N/A N/A | Prometheus Biosciences Inc. | RXDX | McKenna Mark C. Chairman, President & CEO | 25,000 | $2.9 | 338,777 (Direct) | View |
| 2023-03-15 Exercise | 2023-03-17 9:02 pm | N/A 2029-11-06 | Prometheus Biosciences Inc. | RXDX | McKenna Mark C. Chairman, President & CEO | 25,000 | $0 | 338,777 (Direct) | View |
| 2023-03-01 Exercise | 2023-03-03 9:30 pm | N/A N/A | Prometheus Biosciences Inc. | RXDX | McKenna Mark C. Chairman, President & CEO | 11,320 | $3.7 | 1,029,214 (Direct) | View |
| 2023-03-01 Exercise | 2023-03-03 9:30 pm | N/A 2030-12-17 | Prometheus Biosciences Inc. | RXDX | McKenna Mark C. Chairman, President & CEO | 11,320 | $0 | 1,029,214 (Direct) | View |
| 2023-02-15 Exercise | 2023-02-17 9:31 pm | N/A N/A | Prometheus Biosciences Inc. | RXDX | McKenna Mark C. Chairman, President & CEO | 25,000 | $2.9 | 1,363,547 (Direct) | View |
| 2023-02-16 Exercise | 2023-02-17 9:31 pm | N/A N/A | Prometheus Biosciences Inc. | RXDX | McKenna Mark C. Chairman, President & CEO | 38,680 | $3.7 | 1,363,547 (Direct) | View |
| 2023-02-15 Exercise | 2023-02-17 9:31 pm | N/A 2029-11-06 | Prometheus Biosciences Inc. | RXDX | McKenna Mark C. Chairman, President & CEO | 63,680 | $0 | 1,363,547 (Direct) | View |
| 2023-01-17 Exercise | 2023-01-19 8:39 pm | N/A N/A | Prometheus Biosciences Inc. | RXDX | McKenna Mark C. Chairman, President & CEO | 25,000 | $2.9 | 388,777 (Direct) | View |
| 2023-01-17 Exercise | 2023-01-19 8:39 pm | N/A 2029-11-06 | Prometheus Biosciences Inc. | RXDX | McKenna Mark C. Chairman, President & CEO | 25,000 | $0 | 388,777 (Direct) | View |
| 2022-12-09 Option Award | 2022-12-13 8:32 pm | N/A 2032-12-08 | Prometheus Biosciences Inc. | RXDX | McKenna Mark C. Chairman, President & CEO | 166,043 | $0 | 184,074 (Direct) | View |
| 2022-05-20 Option Award | 2022-05-20 7:11 pm | 2025-05-20 2032-05-19 | Prometheus Biosciences Inc. | RXDX | McKenna Mark C. Chairman, President & CEO | 246,639 | $0 | 246,639 (Direct) | View |
| 2021-12-01 Exercise | 2021-12-03 7:02 pm | N/A N/A | Prometheus Biosciences Inc. | RXDX | McKenna Mark C. Chairman, President & CEO | 15,400 | $2.9 | 137,931 (Direct) | View |
| 2021-12-01 Exercise | 2021-12-03 7:02 pm | N/A 2029-11-06 | Prometheus Biosciences Inc. | RXDX | McKenna Mark C. Chairman, President & CEO | 15,400 | $0 | 137,931 (Direct) | View |
| 2021-11-14 Option Award | 2021-11-16 9:03 pm | N/A 2031-11-13 | Prometheus Biosciences Inc. | RXDX | McKenna Mark C. Chairman, President & CEO | 290,000 | $0 | 290,000 (Direct) | View |
Ownership | 2021-03-11 9:26 pm | N/A 2029-11-06 | Prometheus Biosciences Inc. | RXDX | McKenna Mark C. President and CEO | 0 | $0 | 1,624,809 (Direct) | View |